SecSonar.com

Bicycle Therapeutics plc (BCYC)

Bicycle Therapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Bicycle Therapeutics plc (BCYC) is a Biotechnology company based in GB with a market capitalization of $325.5M. Revenue grew 105.8% year-over-year and free cash flow was negative at -$252M. This page tracks BCYC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

GB · 305 employees · IPO May 23, 2019

Valuation

Valuation & price

$4.57 · as of May 26, 2026 · -48.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.53

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$8.71$6.34$3.96Jul 25Dec 25Jul 26Jul 7, 25$7.17Jul 9, 25$8.00Jul 11, 25$8.00Jul 15, 25$7.68Jul 17, 25$8.04Jul 21, 25$8.31Jul 23, 25$8.71Jul 25, 25$8.70Jul 29, 25$8.52Jul 31, 25$8.52Aug 4, 25$8.05Aug 6, 25$7.56Aug 11, 25$7.46Aug 13, 25$7.35Aug 15, 25$7.44Aug 19, 25$7.18Aug 21, 25$7.09Aug 25, 25$7.12Aug 27, 25$7.00Aug 29, 25$7.38Sep 3, 25$7.10Sep 5, 25$7.16Sep 9, 25$7.12Sep 11, 25$7.02Sep 16, 25$6.95Sep 18, 25$7.16Sep 22, 25$7.13Sep 24, 25$7.58Sep 26, 25$7.40Sep 30, 25$7.74Oct 2, 25$8.53Oct 6, 25$8.23Oct 8, 25$8.26Oct 10, 25$8.32Oct 14, 25$7.90Oct 16, 25$8.65Oct 21, 25$8.29Oct 23, 25$7.81Oct 27, 25$8.12Oct 29, 25$8.18Oct 31, 25$8.07Nov 4, 25$6.87Nov 6, 25$6.51Nov 10, 25$6.58Nov 12, 25$6.56Nov 14, 25$6.48Nov 18, 25$6.47Nov 20, 25$6.17Nov 25, 25$6.87Nov 28, 25$7.48Dec 2, 25$6.87Dec 4, 25$7.14Dec 8, 25$7.40Dec 10, 25$7.52Dec 12, 25$7.45Dec 16, 25$7.31Dec 18, 25$6.77Dec 22, 25$7.19Dec 24, 25$6.99Dec 29, 25$6.78Jan 2, 26$6.68Jan 6, 26$6.57Jan 8, 26$6.63Jan 12, 26$6.58Jan 14, 26$6.62Jan 16, 26$6.51Jan 21, 26$6.90Jan 23, 26$6.95Jan 27, 26$7.07Jan 29, 26$6.52Feb 2, 26$6.49Feb 4, 26$5.72Feb 9, 26$5.78Feb 11, 26$5.54Feb 13, 26$5.24Feb 18, 26$5.38Feb 20, 26$5.37Feb 24, 26$5.62Feb 26, 26$5.64Mar 2, 26$5.73Mar 4, 26$5.63Mar 6, 26$5.20Mar 10, 26$5.30Mar 12, 26$5.04Mar 17, 26$5.07Mar 19, 26$4.55Mar 23, 26$4.34Mar 25, 26$4.68Mar 27, 26$4.31Mar 31, 26$4.64Apr 2, 26$5.05Apr 7, 26$4.90Apr 9, 26$4.97Apr 13, 26$4.98Apr 15, 26$5.28Apr 17, 26$5.33Apr 22, 26$4.99Apr 24, 26$4.84Apr 28, 26$4.69Apr 30, 26$4.72May 4, 26$4.94May 6, 26$5.15May 8, 26$4.81May 12, 26$4.72May 14, 26$4.67May 18, 26$4.36May 20, 26$4.42May 22, 26$4.55May 28, 26$4.67Jun 1, 26$4.53Jun 3, 26$4.20Jun 5, 26$4.20Jun 9, 26$4.17Jun 11, 26$4.10Jun 15, 26$4.15Jun 17, 26$4.04Jun 22, 26$3.98Jun 24, 26$3.96Jun 26, 26$4.10Jul 2, 26$4.35
$3.9652-week range$8.87
Loading valuation history…

Fundamentals

Key fundamentals

$325.5M

Market cap

105.8%

Revenue growth (YoY)

100.0%

Gross margin

-$252M

Free cash flow (USD)

-$610.6M

Net debt

Net cash position

19.0%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$2.1MFY 2018$7.1MFY 2019$13.8MFY 2020$10.4MFY 2021$11.7MFY 2022$14.5MFY 2023$27.0MFY 2024$35.3MFY 2025$72.6M
$0$72.6M

Free cash flow by year

2016 → 2025

FY 2016$-11.5MFY 2017$-2.5MFY 2018$-27.3MFY 2019$-30.2MFY 2020$-19.0MFY 2021$-16.8MFY 2022$-105.1MFY 2023$-63.6MFY 2024$-166.0MFY 2025$-252.0M
-$11.5M-$252M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023-480.1%FY 2024-390.3%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual General Meeting ResultsJun 18, 2026Filing
  • 8-K eventClinical Data PresentationMay 21, 2026Filing
  • 8-K eventFirst Quarter 2026 ResultsApr 30, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing
  • 8-K eventProgram UpdateApr 20, 2026Filing

Questions

Frequently asked questions

What is Bicycle Therapeutics plc's market cap?

Bicycle Therapeutics plc (BCYC) has a market capitalization of $325.5M.

What is BCYC's P/E ratio?

A meaningful P/E ratio is not available for BCYC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is BCYC's price-to-book (P/B) ratio?

BCYC trades at 0.53 times book value per share.

Are insiders buying BCYC stock?

SEC Form 4 filings show no open-market insider buys at Bicycle Therapeutics plc in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

EVMN

Evommune, Inc.

$324.9M

OABI

OmniAb, Inc.

$323.4M

SLN

Silence Therapeutics plc

$320.4M

EDIT

Editas Medicine, Inc.

$331.4M

FATE

Fate Therapeutics, Inc.

$317M

CMPX

Compass Therapeutics, Inc.

$334M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.